Cognitive Problems in Patients with HIV

Sahar Ansari. MD
Psychiatrist, psychosomatic fellowship
Assistant professor OF TUMS
Psychosomatic research center

Overview of HIV and its Impact on the Brain:

1

HIV Entry

HIV enters the central nervous system early in infection, crossing the blood-brain barrier.

2

Neuroinflammation

The virus triggers chronic inflammation, damaging neural tissue over time.

3

Cognitive Decline

Prolonged infection can lead to various cognitive deficits, affecting daily functioning.



Neurological Mechanisms Underlying HIV-Related Cognitive Problems:

1

Viral Invasion

HIV enters the brain, infecting microglia and astrocytes.

2

Inflammation

Chronic neuroinflammation leads to the release of neurotoxic substances.

3

Synaptic Damage

Neuronal connections are disrupted,

4

Brain Atrophy

Long-term damage results in loss of brain volume in key areas.

Prevalence of Cognitive Impairment in HIV Patients



1 **High Prevalence**

Up to 50% of HIV patients experience some form of cognitive impairment.

2 **Varying Severity**

Impairment ranges from mild cognitive difficulties to severe dementia in advanced cases.

3 **Aging Population**

Prevalence increases with age, as HIV patients live longer with improved treatments.

HIV-associated neurocognitive disorders (HAND):
Depending on the severity and impact on daily functioning, cognitive deficits can be classified into three conditions:

- asymptomatic neurocognitive impairment (ANI),
- HIV-associated mild neurocognitive disorder (MND),
- HIV-associated dementia (HAD).

HIV-associated dementia-HAD:

- untreated patients with advanced HIV infection.
- primarily characterized by subcortical dysfunction.
- attention-concentration impairment, depressive symptoms, psychomotor speed.
- The onset is subacute.
- Cerebral atrophy and diffuse or patchy white matter hyperintensity.

MND:

- The onset and time course is generally slower than HAD.
- deficits may remain stable or unchanged for years.
- There are no specific imaging findings.



Types of Cognitive Deficits Seen in HIV: MND OR HAD

When these occur without an evident caus other than HIV infection.

Memory Problems

Difficulties in forming new memories and recalling information are common.

Attention Deficits

Reduced ability to concentrate and maintain focus on tasks.

Executive Function

Impaired decision-making, planning, and problem-solving skills. speed of informational processing

Motor Skills-mood

Slowed reflexes and reduced coordination in advanced stages.apathy,lethargy,emotional response,abulia

Factors Contributing to Cognitive Issues:

Viral Factors

Viral load
CD4 count 500 cells/dl or less

.

Treatment Factors

Antiretroviral toxicity.
Treatment adherence and effectiveness.

Comorbidities

Substance abuse.
Mental health issues (depression)
Low level of education
older age
cardiovascular and metabolic dis.

Diagnostic Approaches for Assessing Cognitive Function

Neuropsychological Tests

Neuroimaging

MRI and PET scans
brain structure and function.

Biomarkers

Analysis of CSF and blood markers

Clinical Assessment

Hx ,Phx

Screening for deficits:

- The value of broadly screening patients with HIV for neurocognitive impairment is controversial.

Evaluation

Initial assessment:

- Time course, and functional impact of any cognitive deficits.
- Establish the stage of HIV disease and treatment status.
- Other potential causes of cognitive symptoms (DDx).

Further evaluation:

- Patients with very mild symptoms, without functional impairment in work or daily life, and without recent onset or progression, it is reasonable to follow symptoms and signs without more neurological evaluation.
- Patients with severe deficits, MRI and LP for evaluating for other etiologies.

Screening for deficits can be done by inquiring about symptoms and/or performing brief neurocognitive tests in the clinic.

Some experts have suggested the following series of questions :

1) ●Do you experience frequent memory loss (eg, do you forget the occurrence of special events, even the more recent ones, appointments, etc.)?

2) ●Do you feel that you are slower when reasoning, planning activities, or solving problems?

3) ●Do you have difficulties paying attention (eg, to a conversation, a book, or a movie)?

For each question, patients can answer
"never,“
"hardly ever,"
"yes, definitely.“

A "yes, definitely" answer to any of the three questions can prompt further evaluation.

DIFFERENTIAL DIAGNOSIS:

Central nervous system (CNS) infections:

CD4 cell counts <200 : toxoplasmosis, Cryptococcal meningitis,**CMV**

CNS malignancy :

depending on the location of the mass, it may present only with changes in cognition and behavior.

Alzheimer disease:

early and relatively isolated memory loss followed by other "cortical" abnormalities, such as aphasia and apraxia.

CSF biomarkers of Alzheimer's disease (t- and p-tau and amyloid beta 1-42) or amyloid positron emission tomographic (PET) scanning.

DIFFERENTIAL DIAGNOSIS:

VASCULAR DEMENTIA:

present much like HAD with subcortical features but is usually distinguished by a background of hypertension, episodes of lacunar stroke, and distinct MRI findings.

Nutritional deficiencies (vitamin B12 deficiency) :

Cognitive impairment secondary to vitamin B12 deficiency can be accompanied by other neurologic symptoms, including paresthesias and sensory deficits. Vitamin B12 deficiency is common in HIV.

Endocrine disorders :

(eg, thyroid dysfunction and adrenal insufficiency) – Hormonal aberrations are also frequent findings in HIV infection and can lead to confusion and other cognitive deficits.

DIFFERENTIAL DIAGNOSIS:

Severe substance use or psychiatric disorder:

These are frequent comorbidities and confounders in the diagnosis of HAND and are often evident on detailed history.

Delirium :

Patients with delirium have a reduced ability to sustain, focus, or shift attention, which occurs over a short period of time.

Polypharmacy :

Various drugs, in particular anticholinergic agents, opioids, and anxiolytics, can negatively impact cognition.

Drugs believed to cause or prolong delirium or confusional states*

Analgesics
NSAIDs
Opioids (especially meperidine)
Antibiotics and antivirals
Acyclovir
Aminoglycosides
Amphotericin B
Antimalarials
Cephalosporins
Cycloserine
Fluoroquinolones
Isoniazid
Interferon
Linezolid
Macrolides
Metronidazole
Nalidixic acid
Penicillins
Rifampin
Sulfonamides
Anticholinergics
Atropine
Benztropine
Diphenhydramine
Scopolamine
Trihexyphenidyl
Antiseizure medications
Carbamazepine
Levetiracetam
Phenytoin
Valproate
Vigabatrin
Antidepressants
Mirtazapine
Selective serotonin reuptake inhibitors
Tricyclic antidepressants
Cardiovascular and hypertension drugs
Antiarrhythmics
Beta blockers
Clonidine
Digoxin
Diuretics
Methyldopa

Corticosteroids
Dopamine agonists
Amantadine
Bromocriptine
Levodopa
Pergolide
Pramipexole
Ropinirole
Gastrointestinal agents
Antiemetics
Antispasmodics
Histamine 2 receptor blockers
Loperamide
Herbal preparations
Atropa belladonna extract
Henbane
Mandrake
Jimson weed
St. John's wort
Valerian
Hypoglycemics
Hypnotics and sedatives
Barbiturates
Benzodiazepines
Muscle relaxants
Baclofen
Cyclobenzaprine
Other CNS-active agents
Disulfiram
Cholinesterase inhibitors (eg, donepezil)
Interleukin 2
Lithium
Phenothiazines

NSAIDs: nonsteroidal antiinflammatory drugs; CNS: central nervous system.

* Not exhaustive, all medications should be considered.

MRI of the brain from a patient with HIV-associated dementia



Bilateral symmetrical high T2 signals without mass effect are present in the white matter of both frontal lobes, associated with subcortical atrophy.

MRI: Magnetic resonance imaging.

UpToDate®

Treatment Strategies for Managing Cognitive Impairment: ART + Adjunctive therapy

Antiretroviral Therapy	**Optimize HIV treatment to reduce viral load in the brain**
Cognitive Rehabilitation	**Targeted exercises to improve specific cognitive functions**
Neuroprotective Agents	**Medications to reduce inflammation and protect neurons**
Lifestyle Modifications	**Exercise, nutrition, and sleep hygiene to support brain health**

Treatment Strategies for Managing Cognitive Impairment:

In a separate analysis of the same post-ART cohort, study:

- Asymptomatic neurocognitive impairment (ANI) =33%
- Mild neurocognitive disorder(MND) =12%
- HAD =2 % of 1316 patients with HIV



Importance of Early Intervention and Ongoing Monitoring

Early Detection

Regular cognitive screenings can identify subtle changes before significant impairment occurs.

Continuous Monitoring

Ongoing assessment allows for timely adjustments in treatment and support strategies.

1

2

3

Prompt Treatment

Early intervention can slow or halt cognitive decline, preserving function.

Integrated care models:

Addressing physical and mental health aspects is vital in optimizing treatment outcomes and promoting mental well-being in this population.


Dx & stages of HAND
Diagnostic Tools
Differentials diagnosis
HX ,PH/E,LAB TEST
Neuropsychological Tests
MRI ,LP
TREATMENT STRATEGIES
ART
Adjunctive therapy(cog rehab,…)
Tx of comorbid mental and physical diseases

MANAGEMENT:

Diagnosis and treatment of HAND involves a multifaceted approach:

Efficacy of ART for HAND :
ART has a clear beneficial effect on the treatment and prevention of HAD, The impact of ART on the milder forms of HAND (ie, MND and ANI) is not as clear.

Adjunctive therapies:
including cognitive rehabilitation, pharmacological interventions, and psychosocial support, play crucial roles in managing cognitive symptoms and enhancing overall quality of life.

Adjunctive therapy :

Optimizing Patient Outcomes and Quality of Life

Physical Activity

Regular exercise improves cognitive function and overall well-being.

Social Engagement

Social interactions stimulate the brain and provide emotional support.

Cognitive Training

Brain exercises and puzzles can help maintain and improve cognitive skills.

Adjunctive therapy

1-**Antioxidants**: neuroprotective properties

N-Acetylcysteine, Coenzyme Q10, Omega-3 Fatty Acid

2-**Psychostimulants**: improve attention and cognitive function

Methylphenidate, modafinil

3-**Cognitive rehabilitation**:

training and strategies to help individuals with HAND improve their daily functioning, memory, and problem-solving skills.

Adjunctive therapy :

4-**Comorbid condition management:**

depression, anxiety, substance use disorders, and cardiovascular risk factors are crucial. Treating these conditions can indirectly improve cognitive function and overall well-being

5- **Supportive care:**

mental health counseling, occupational therapy, and social support

6-**Personalized treatment plans:**

Adjunctive therapy :

Mental health implications:

1-Depression and anxiety:

The cognitive deficits associated with HAND can contribute to feelings of helplessness, frustration, and reduced self-esteem, leading to depressive and anxiety symptoms.

2-Stigma and social isolation:

stigma and discrimination due to cognitive deficits, leading to social isolation reduced social interactions, feelings of shame, and decreased self-confidence,self efficacy.

Addressing stigma through education, support groups, and counseling to cope with these psychosocial challenges.

Adjunctive therapy :

Mental health implications:

3-Impaired daily functioning:

difficulties with memory, attention, executive functions, and problem-solving. These cognitive impairments can impact employment, financial management, and medication adherence, increasing stress and decreasing self-efficacy.

Occupational therapy

4-Reduced quality of life:

Affects multiple domains of life, including work, relationships, and leisure activities, leading to a diminished sense of well-being and satisfaction.

Adjunctive therapy :

Mental health implications:

5-**Treatment adherence challenges:**

Due to cognitive deficits, such as forgetfulness, poor medication management, and difficulties following complex treatment schedules.

- medication reminders, cognitive aids(booklet,cheklist,flowchart), and support systems, to optimize treatment outcomes and mental health.

Adjunctive therapy :

Mental health implications:

6-**Impact on caregivers:**

Caregivers may experience increased burden, stress, and emotional challenges in providing care and support to individuals with cognitive impairment.

Support services and caregiver interventions are essential to ensure their resilience and ability to provide adequate care.

These issues are not yet fully resolved?!

- milder cognitive impairment in virally suppressed patients is a residual effect of earlier, subclinical brain injury that developed before treatment was started ???(when should we use psychological tests?)
- Can brain injury continue despite effective viral suppression???
- Additionally, the degree to which the cognitive impairments in treated patients can be attributed to HIV infection itself is unclear ('Comorbidities').
- Finally, there is concern that ART itself may have chronic toxic effects on the brain.

2023 Mar 1;146(3):801-802.
doi: 10.1093/brain/awad035.

Is neurocognitive ageing accelerated in virally suppressed people with HIV and multimorbidity?

Lucette A Cysique[1 2 3], Bruce J Brew[1 2 4]

Conclusions:

- Overall, research efforts should continue to advance our understanding of HAND and its underlying mechanisms and explore innovative therapeutic approaches to enhance cognitive function and improve mental health outcomes.

- Early detection, prompt management, and ongoing monitoring can significantly improve the quality of life and overall well-being of individuals with HIV.